by Peter Ciszewski | Nov 13, 2017
Philippe M. Maitre, Executive Vice President, US Operations discusses Onxeo and the company’s focus on orphan oncology products. Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the...
by Peter Ciszewski | Nov 13, 2017
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses the potential market for Iomab-B. Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. BC8 is linked to...
by Peter Ciszewski | Nov 12, 2017
Amit Rakhit, MD, Chief Medical and Portfolio Officer at Ovid Therapeutics, provides an overview of Fragile X syndrome. Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment....
by Peter Ciszewski | Nov 12, 2017
Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses his company’s focus and how it is developing drugs for patients with rare disorders.
by Peter Ciszewski | Nov 7, 2017
Len Walt, Vice President, Head of Medical Affairs, Sobi in North America, discusses neonatal onset multisystem inflammatory disease (NOMID), a disorder that causes persistent inflammation and tissue damage primarily affecting the nervous system, skin, and joints....
